<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01536210</url>
  </required_header>
  <id_info>
    <org_study_id>YY-162 (b)</org_study_id>
    <nct_id>NCT01536210</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract in Children With ADHD(Attention Deficit Hyperactivity Disorder)</brief_title>
  <acronym>ADHD</acronym>
  <official_title>Randomized, Double-Blind, Placebo-control, Multicenter Study, the Efficacy and Safety of Combination of Ginkgo Extract and Ginseng Extract(YY-162)in Children With ADHD(Attention Deficit Hyperactivity Disorder)in 8 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuyu Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuyu Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate clinical efficacy and safety of treatment with YY-162 in children
      with ADHD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is Double-Blind, two arms, multi-center, Interventional, 8 weeks study starting with
      YY-162(Combination of Ginkgo extract and Ginseng extract)in children with ADHD. Assessment of
      efficacy and safety will be performed at the baseline, weeks 2, 4 and 8. At the first visit,
      a full psychiatric history, demographic date and physical examination will be undertaken.
      Throughout the study, the following procedures, documentations and evaluations will
      performed; K-ARS, IOWA conner's rating scale, CGI-S/I, ATA, Children's color trails test and
      stroop test, intelligence test(from KEDI-WISC)and adverse event reporting.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Korea-ADHD Rating scale</measure>
    <time_frame>within the first 8 weeks (plus or minus 5 days) after adminitration</time_frame>
    <description>Validated questionnaire about core ADHD symptoms(Korea-ADHD Rating scale) filled out by patents at baseline, after 8 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IOWA conner's rating scale</measure>
    <time_frame>baseline, after 2, 4, and 8 weeks</time_frame>
    <description>Validated questionnaire about core ADHD symptoms(IOWA Conner's rating scale) filled out by parents at baseline, after 2,4 weeks and closeout</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression(Severity and Improvement)</measure>
    <time_frame>baseline, after 2, 4, and 8 weeks</time_frame>
    <description>Clinical Global Impression(Severity and Improvement)rated by treating physician at baseline, after2,4 weeks and closeout</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Advanced Test of Attention</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <description>Advanced Test of Attention and baseline and closeout Attention Diagnostic system(visual and auditory) at baseline and closeout</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>children's color trails test and stroop test</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <description>Children's color trails test and stroop test at baseline and closeout</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intelligence test(from KEDI-WISC)</measure>
    <time_frame>screening and 8 weeks</time_frame>
    <description>Intelligence test(from KEDI-WISC)at screening and closeout</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Mental Disorders</condition>
  <arm_group>
    <arm_group_label>YY-162</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>YY-162(Ginkgo Extract 30mg + Ginseng Extract 50mg)
1T/Three times a day(Tid) for 8 weeks, PO medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1T /Three times a day(Tid) for 8 weeks, PO medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YY-162</intervention_name>
    <description>YY-162(Ginkgo extract 30mg + Ginseng extract 50mg) 1T/Three times a day(Tid) for 8 weeks, PO medication</description>
    <arm_group_label>YY-162</arm_group_label>
    <other_name>combination of Ginkgo extract and Ginseng extract</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 1T/ Three times a day (tid) for 8 weeks, PO medication</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mele and female subjects aged from 6 to 15

          -  Subjects must meet DSM-IV criteria for ADHD based-on the K-Schedule for affective
             disorder and schizophrenia(K-SADS-PL-K)interview

          -  Subjects signed a written consent form voluntarily

          -  Patient's assent to participate in the study and written informed consent form signed
             by one of the parents, parent surrogates or legal guardian.

          -  Subjects who can keep visit schedule and whose parent/parent surrogates or legal
             guardian can willingly complete assessments defined in the study protocol.

          -  Subjects/parents, parent surrogates or legal guardian who can understand the
             participation of the study and voluntarily withdraw from the study at any time.

        Exclusion Criteria:

          -  Subjects who have difficulty swallowing tablet.

          -  Subjects who have known allergy to plant extracts.

          -  Subjects who meet DSM-IV diagnostic criteria for current major depressive disorder or
             anxiety disorder requiring drug therapy.

          -  Subjects who have any history of bipolar disorder, psychotic disorder, and substance
             use disorder, have been diagnosed with a pervasive developmental disorder, organic
             brain disease and seizure disorder.

          -  Subjects who have significant suicidal ideation.

          -  Subjects with mental retardation.

          -  Subjects with Tourette's syndrome requiring drug therapy.

          -  Subjects who have been administrated Methylphenidate or Atomoxetine within recent 3
             months and Ginkgo extract or Ginseng extract within recent 1 month.

          -  Subjects who currently have a significant medical conditions(e.g. diseases of
             cardiovascular, hepatic, renal, respiratory, glaucoma)

          -  Subjects who have abnormalities in the ECG or show clinically significant
             abnormalities of laboratory results including serum chemistries and hematology.

          -  subjects who are currently taking alpha-2 adrenergic receptor agonist, antidepressant,
             antipsychotic, benzodiazepines, modafinil, anticonvulsant.

          -  subjects who receive psychosocial treatment during the drug trial.

          -  Subjects who are not able to swallow the study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SooChurl Cho, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>HyunJu Hong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>EunJin Park, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Soochurl Cho, MD,PhD</last_name>
    <phone>82-2-2072-3648</phone>
    <email>soochurl@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kyeongsuk Seo, BS</last_name>
    <phone>82-2-2253-6600</phone>
    <phone_ext>269</phone_ext>
    <email>ksseo@yuyu.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hallym University Hospital</name>
      <address>
        <city>Anyang-si</city>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun Ju Hong, MD,PhD</last_name>
      <phone>82-31-380-3750</phone>
      <email>honghj88@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Kyeongsuk Seo, BS</last_name>
      <phone>82-2-2253-6600</phone>
      <email>ksseog@yuyu.co.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Hyun Ju Hong, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Goyang-Si</city>
        <zip>411-706</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>EunJin Park, MD</last_name>
      <phone>82-31-910-7544</phone>
      <email>uma99@hanmail.net</email>
    </contact>
    <contact_backup>
      <last_name>Kyeongsuk Seo, BS</last_name>
      <phone>82-2-2253-6600</phone>
      <email>ksseo@yuyu.co.kr</email>
    </contact_backup>
    <investigator>
      <last_name>EunJin Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soo-Churl Cho, MD, PhD</last_name>
      <phone>83-2-2072-3648</phone>
      <email>soochurl@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Kyeongsuk Seo, BS</last_name>
      <phone>82-2-2253-6600</phone>
      <email>ksseo@yuyu.co.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Soo-Churl Cho, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed</url>
    <description>Effect of the herbal extract combination Panax quinquifolius and Ginkgo biloba on attention-deficit hyperactivity disorder: a pilot study</description>
  </link>
  <results_reference>
    <citation>Lyon MR, Cline JC, Totosy de Zepetnek J, Shan JJ, Pang P, Benishin C. Effect of the herbal extract combination Panax quinquefolium and Ginkgo biloba on attention-deficit hyperactivity disorder: a pilot study. J Psychiatry Neurosci. 2001 May;26(3):221-8.</citation>
    <PMID>11394191</PMID>
  </results_reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2012</study_first_submitted>
  <study_first_submitted_qc>February 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2012</study_first_posted>
  <last_update_submitted>February 15, 2012</last_update_submitted>
  <last_update_submitted_qc>February 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADHD(attention Deficit Hyperactivity Disorder)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

